<DOC>
	<DOCNO>NCT02470871</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics ( PK ) safety rVIIa-FP ( CSL689 ) total 10 16 male female adult inherit coagulation factor VII ( FVII ) deficiency . Subjects receive single dose routine FVII replacement product ( ie , either recombinant activate coagulation FVII [ rFVIIa , eptacog alfa ( activate ) ] plasma-derived FVII [ pdFVII ] ) comparator , randomly assign single low dose single high dose study product CSL689 ( 8 subject per CSL689 dose level ) . Serial blood sample PK analysis take 24 hour eptacog alfa ( activate ) pdFVII injection , 48 hour CSL689 injection . Subject safety routinely monitor throughout study .</brief_summary>
	<brief_title>Study Pharmacokinetics Safety Recombinant Factor VIIa Fusion Protein ( rVIIa-FP , CSL689 ) Patients With Congenital Factor VII Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Factor VII Deficiency</mesh_term>
	<criteria>Proven congenital FVII deficiency . Age ≥ 18 year . FVII level &lt; 2 % normal level . Minimum 50 previous exposure day pdFVII ( include prothrombin complex concentrate [ PCCs ] ) rFVIIa . History , risk factor , thromboembolic event , include know deep vein thrombosis . Inhibitor FVII rFVIIa , current historic . Known suspected hypersensitivity hamster protein , CSL689 , excipient CSL689 . Known suspect allergy rFVIIa hamster protein . Major surgery within 1 month screening . Advanced atherosclerotic disease ( ie , known history ischemic heart disease , ischemic stroke ) . Human immunodeficiency virus ( HIV ) positive subject cluster differentiation 4 ( CD4 ) + lymphocyte count &lt; 200/µL screening . Use investigational agent within 30 day study . Use concomitant therapy permit study ( ie , platelet inhibitor , desmopressin , fibrinolysis inhibitor , except use local treatment [ eg , oral bleeds ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>